Qurient Co Ltd (115180)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Qurient Co Ltd (115180) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013512
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Qurient Co Ltd (Qurient) is a biotechnology company that focuses on the development of new drugs for unmet medical needs. The company’s portfolio of pipeline products includes Q301, Q203, Q701, 5LO INH and CDK7 INH among others. The company is developing products for the treatment of atopic dermatitis; extensively drug-resistant tuberculosis (XDR)/multi drug resistant (MDR)/ totally drug resistant (TDR) tuberculosis (TB); asthama and cancer. It works in partnership with research institutes, CRO, research hospitals, and CMO for research and development of new therapeutics. Qurient is headquartered in Seongnam, Gyeonggi, South Korea.

Qurient Co Ltd (115180) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Qurient Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Qurient Raises USD15.5 Million in Series F Venture Financing 10
Qurient Raises USD3 Million in Series E Venture Financing 12
Qurient Raises US$4 Million In Venture Financing 13
Quro Science Secures US$1 Million In Venture Financing 14
Partnerships 15
Qurient Enters into Agreement with Lead Discovery Center 15
Licensing Agreements 16
Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 16
Lead Discovery Center Enters into Licensing Agreement with Qurient 17
Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203 18
Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 19
Equity Offering 21
Qurient Raises USD25.7 Million in IPO 21
Qurient Co Ltd – Key Competitors 22
Qurient Co Ltd – Key Employees 23
Qurient Co Ltd – Locations And Subsidiaries 24
Head Office 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Qurient Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Qurient Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Qurient Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Qurient Raises USD15.5 Million in Series F Venture Financing 10
Qurient Raises USD3 Million in Series E Venture Financing 12
Qurient Raises US$4 Million In Venture Financing 13
Quro Science Secures US$1 Million In Venture Financing 14
Qurient Enters into Agreement with Lead Discovery Center 15
Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 16
Lead Discovery Center Enters into Licensing Agreement with Qurient 17
Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203 18
Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 19
Qurient Raises USD25.7 Million in IPO 21
Qurient Co Ltd, Key Competitors 22
Qurient Co Ltd, Key Employees 23

★海外企業調査レポート[Qurient Co Ltd (115180)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TransGenic Inc (2342):企業の財務・戦略的SWOT分析
    TransGenic Inc (2342) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Balkrishna Industries Ltd:企業の戦略・SWOT・財務情報
    Balkrishna Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Balkrishna Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • The Saudi British Bank (1060):企業の財務・戦略的SWOT分析
    The Saudi British Bank (1060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Oncolix Inc-製薬・医療分野:企業M&A・提携分析
    Summary Oncolix Inc (Oncolix) is a clinical stage biopharmaceutical company. It is developing a targeted therapeutic protein, Prolanta for the treatment of ovarian, breast and other cancers. Prolanta is a recombinant analogue to the human prolactin and acts as an antagonist to the prolactin receptor …
  • Transportadora De Gas Del Sur S.A.:企業の戦略・SWOT・財務分析
    Transportadora De Gas Del Sur S.A. - Strategy, SWOT and Corporate Finance Report Summary Transportadora De Gas Del Sur S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Applied Genetic Technologies Corp (AGTC):企業の財務・戦略的SWOT分析
    Summary Applied Genetic Technologies Corp (AGTC) is a pharmaceutical company that provides development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. It offers products such as x-linked retinoschisis, achromatopsia, x-linked retinitis pi …
  • Electricite de France SA (EDF):企業の財務・戦略的SWOT分析
    Electricite de France SA (EDF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company. It discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of n …
  • Enbridge Inc (ENB):企業の財務・戦略的SWOT分析
    Enbridge Inc (ENB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Landsvirkjun hf:企業の戦略的SWOT分析
    Landsvirkjun hf - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Hydrogenics Corp (HYG):企業の財務・戦略的SWOT分析
    Hydrogenics Corp (HYG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Plains All American Pipeline LP (PAA):石油・ガス:M&Aディール及び事業提携情報
    Summary Plains All American Pipeline LP (PAAP) is a midstream energy company. It owns and operates the transportation, storage, terminalling and marketing of crude oil and refined petroleum products. The company also carries out the storage of natural gas, and processing, transportation, fractionati …
  • Enel Generacion Chile SA:企業の発電所・SWOT分析2018
    Enel Generacion Chile SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Biomay AG-製薬・医療分野:企業M&A・提携分析
    Summary Biomay AG (Biomay) discovers and develops disease modifying allergy therapeutics. The company develops peptide carrier fusion vaccines for allergy immunotherapy. Its pipeline product portfolio comprises investigation candidates targeted against IgE mediated diseases, grass pollen allergy, ho …
  • Bianor Holding AD Sofia (5BI):企業の財務・戦略的SWOT分析
    Bianor Holding AD Sofia (5BI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Celgene Corporation:企業のM&A・事業提携・投資動向
    Celgene Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Celgene Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Encycle Corp:電力:M&Aディール及び事業提携情報
    Summary Encycle Corp (Encycle), formerly REGEN Energy Inc, is a clean technology company that develops energy management technology based on swarm logic concepts. The company’s solutions include wireless automated demand management and demand response solutions and swarm energy management solutions. …
  • Mega Uranium Ltd (MGA):企業の財務・戦略的SWOT分析
    Mega Uranium Ltd (MGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Coca-Cola HBC AG:企業の戦略・SWOT・財務情報
    Coca-Cola HBC AG - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola HBC AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • China Construction Bank Corp:企業の戦略・SWOT・財務分析
    China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report Summary China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆